| [1] |
Stypinska B, Wajda A, Walczuk E, et al. The serum cell-free microRNA expression profile in MCTD, SLE, SSc, and RA patients [J]. J Clin Med, 2020, 9(1): 161.
|
| [2] |
Madieh J, Khamayseh I, Hrizat A, et al. Scleroderma renal crisis in a case of mixed connective tissue disease treated successfully with angiotensin-converting enzyme inhibitors [J]. Case Rep Nephrol, 2021, 2021: 8862405.
|
| [3] |
Xu C, Wang F, Chen Y, et al. ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury [J]. Am J Physiol Renal Physiol, 2020, 318(5): F1122-F1135.
|
| [4] |
Li Y, Yang X, Ouyang S, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: a preliminary study [J]. Clin Exp Hypertens, 2020, 42(3): 239-243.
|
| [5] |
Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue disease [J]. J Autoimmun, 2014, 48-49: 46-49.
|
| [6] |
Gunnarsson R, Hetlevik SO, Lilleby V, et al. Mixed connective tissue disease [J]. Best Pract Res Clin Rheumatol, 2016, 30(1): 95-111.
|
| [7] |
Rasmussen EK, Ullman S, Høier-Madsen M, et al. Clinical implications of ribonucleoprotein antibody [J]. Arch Dermatol, 1987, 123(5): 601-605.
|
| [8] |
Batal I, Domsic RT, Medsger TA, et al. Scleroderma renal crisis: a pathology perspective [J]. Int J Rheumatol, 2010, 2010: 543704.
|
| [9] |
Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement [J]. Clin Exp Rheumatol, 2003, 21(3 Suppl 29): S29-S31.
|
| [10] |
Denton CP, Lapadula G, Mouthon L, et al. Renal complications and scleroderma renal crisis [J]. Rheumatology (Oxford), 2009, 48(Suppl 3): iii32-iii35.
|
| [11] |
Chaves-Almagro C, Castan-Laurell I, Dray C, et al. Apelin receptors: from signaling to antidiabetic strategy [J]. Eur J Pharmacol, 2015, 763(Pt B): 149-159.
|
| [12] |
Wang Z, Yu D, Wang M, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems [J]. Sci Rep, 2015, 5(1): 1-8.
|
| [13] |
Chen Y, Xu C. The interaction partners of (pro)renin receptor in the distal nephron [J]. FASEB J, 2020, 34(11): 14136-14149.
|
| [14] |
Kuba K, Sato T, Imai Y, et al. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology [J]. Peptides, 2019, 111: 62-70.
|
| [15] |
Mouthon L, Bérezné A, Bussone G, et al. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis [J]. Clin Rev Allergy Immunol, 2011, 40(2): 84-91.
|
| [16] |
Mouthon L, Bussone G, Berezné A, et al. Scleroderma renal crisis [J]. J Rheumatol, 2014, 41(6): 1040-1048.
|
| [17] |
Cozzi F, Marson P, Cardarelli S, et al. Prognosis of scleroderma renal crisis: a long-term observational study [J]. Nephrol Dial Transplant, 2012, 27(12): 4398-4403.
|
| [18] |
Nagaraja V. Management of scleroderma renal crisis [J]. Curr Opin Rheumatol, 2019, 31(3): 223-230.
|
| [19] |
Zhang Y, Wang Y, Luo M, et al. Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway [J]. Peptides, 2019, 114: 29-37.
|
| [20] |
Chen H, Wang L, Wang W, et al. ELABELA and an ELABELA fragment protect against AKI [J]. J Am Soc Nephrol, 2017, 28(9): 2694-2707.
|